Characteristic | TOTAL | Genotype 1 | Genotype 2 | Genotype 3 | Genotype 4 | |||||
---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | |
Age category, n (%) | ||||||||||
 18–45 | 1635 | 32.2 | 386 | 22.4 | 299 | 28.6 | 948 | 41.1 | 2 | 66.7 |
 45–60 | 2838 | 55.9 | 944 | 54.8 | 630 | 60.2 | 1264 | 54.8 | . | . |
 60+ | 606 | 11.9 | 394 | 22.9 | 118 | 11.3 | 93 | 4.0 | 1 | 33.3 |
Gender, n (%) | ||||||||||
 Female | 698 | 13.7 | 486 | 28.2 | 101 | 9.6 | 110 | 4.8 | 1 | 33.3 |
 Male | 4381 | 86.3 | 1238 | 71.8 | 946 | 90.4 | 2195 | 95.2 | 2 | 66.7 |
HCV RNA categories, n (%) | ||||||||||
 < 800,000 IU/mL | 2922 | 57.7 | 901 | 52.5 | 625 | 59.8 | 1393 | 60.5 | 3 | 100.0 |
 ≥ 800,000 IU/mL | 2145 | 42.3 | 816 | 47.5 | 420 | 40.2 | 909 | 39.5 | . | . |
FIB-4 Test | ||||||||||
 < 1.45 | 200 | 5.7 | 65 | 6.0 | 51 | 7.0 | 84 | 5.0 | . | . |
 1.45–3.25 | 1763 | 50.2 | 491 | 45.0 | 403 | 55.1 | 868 | 51.5 | 1 | 50.0 |
 > 3.25 | 1546 | 44.1 | 535 | 49.0 | 277 | 37.9 | 733 | 43.5 | 1 | 50.0 |
Metavir score | ||||||||||
 < F4 | 2021 | 42.1 | 676 | 39.8 | 516 | 50.9 | 827 | 39.6 | 2 | 66.7 |
 F4 | 2783 | 57.9 | 1021 | 60.2 | 497 | 49.1 | 1264 | 60.4 | 1 | 33.3 |
Liver function tests, n (%) | ||||||||||
 ALT >2 X ULN | 2585 | 51.0 | 731 | 42.5 | 466 | 44.6 | 1385 | 60.2 | 3 | 100.0 |
 AST >2 X ULN | 2604 | 51.4 | 783 | 45.6 | 442 | 42.3 | 1376 | 59.8 | 3 | 100.0 |
 Billirubin >1.1 mg/dL | 4423 | 87.3 | 1520 | 88.5 | 928 | 88.8 | 1972 | 85.7 | 3 | 100.0 |
 Albumin < 35 g/L | 2001 | 39.5 | 670 | 39.0 | 469 | 44.9 | 862 | 37.4 | . | . |
 INR >1.49 | 687 | 13.6 | 260 | 15.1 | 132 | 12.6 | 295 | 12.8 | . | . |
Co-infections, n (%) | ||||||||||
 HBsAg+ | 108 | 2.2 | 28 | 1.7 | 19 | 1.9 | 61 | 2.8 | . | . |
 HBsAg- | 4777 | 97.8 | 1666 | 98.3 | 985 | 98.1 | 2123 | 97.2 | 3 | 100.0 |
Treatment regimen, n (%) | ||||||||||
 IFN/SOF/RBV (12 wk) | 2646 | 52.1 | 905 | 52.5 | 240 | 22.9 | 1500 | 65.1 | 1 | 33.3 |
 SOF/RBV (12 wk) | 364 | 7.2 | 3 | 0.2 | 360 | 34.4 | 1 | 0 | . | . |
 SOF/RBV (20 wk) | 395 | 7.8 | 3 | 0.2 | 392 | 37.4 | . | . | . | . |
 SOF/RBV (24 wk) | 1418 | 27.9 | 695 | 40.3 | 7 | 0.7 | 714 | 31 | 2 | 66.7 |
 SOF/RBV (48 wk) | 256 | 5 | 118 | 6.8 | 48 | 4.6 | 90 | 3.9 | . | . |
City of treatment site, n (%) | ||||||||||
 Tbilisi | 3800 | 74.8 | 1294 | 75.1 | 819 | 78.2 | 1684 | 73.1 | 3 | 100 |
 Kutaisi | 362 | 7.1 | 148 | 8.6 | 72 | 6.9 | 142 | 6.2 | . | . |
 Batumi | 501 | 9.9 | 177 | 10.3 | 67 | 6.4 | 257 | 11.1 | . | . |
 Zugdidi | 328 | 6.5 | 90 | 5.2 | 81 | 7.7 | 157 | 6.8 | . | . |
 Gori | 42 | 0.8 | 6 | 0.3 | 5 | 0.5 | 31 | 1.3 | . | . |
 Rustavi | 40 | 0.8 | 9 | 0.5 | 3 | 0.3 | 28 | 1.2 | . | . |
 Lanchkhuti | 4 | 0.1 | . | . | . | . | 4 | 0.2 | . | . |
 Gurjaani | 2 | 0 | . | . | . | . | 2 | 0.1 | . | . |